Adaptive Phase I-II Clinical Trial of Preventive Vaccine Consisting of Autologous Dendritic Cells Previously Incubated With S-protein From Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2), in Subjects Negative for COVID-19 Infection and Anti-SARS-CoV-2 Antibodies
Latest Information Update: 08 May 2023
At a glance
- Drugs AV-COVID-19 (Primary) ; Granulocyte macrophage colony stimulating factor
- Indications COVID 2019 infections
- Focus Adverse reactions
- Sponsors AiVita Biomedical
Most Recent Events
- 01 May 2023 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 14 Dec 2021 Planned End Date changed from 1 Jan 2023 to 1 Jan 2024.
- 14 Dec 2021 Planned primary completion date changed from 1 Jun 2022 to 1 Jun 2023.